ICICI Prudential Nifty Pharma Index Fund
ICICI Prudential Mutual Fund · Index Funds (Equity) · Direct Growth · AMFI 150930 · ISIN INF109KC11M9
NAV₹21.971720 Nov 2026
3Y return+21.62%a year
5Y return—a year
Expense ratio0.51%₹177 Cr
Growth Score82.8★★★★★
Returns
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | Since launch |
| Fund | +10.79% | +7.38% | +14.44% | +25.12% | +25.25% | +21.62% | — | — | — | +22.33% |
| NIFTY Pharma TRI | +10.85% | +7.49% | +14.67% | +25.66% | +25.86% | +22.31% | +16.87% | — | — | — |
| Category middle | +8.41% | +0.48% | +6.20% | +2.07% | +1.17% | +11.34% | +8.84% | +12.47% | +13.25% | — |
Risk (36 months)
| Volatility | 14.95% |
| Sharpe | 1.01 |
| Sortino | 1.67 |
| Beta | 1.00 |
| Alpha | -0.32% |
| Deepest fall | -16.59% |
| 1-year periods with a loss | 9% |
| 5Y SIP XIRR | — |
Top holdings (31 Oct 2026)
| Sun Pharmaceutical Industries Ltd. | 18.60% |
| Divi's Laboratories Ltd. | 12.28% |
| Laurus Labs Ltd. | 9.26% |
| Dr. Reddy's Laboratories Ltd. | 8.15% |
| Cipla Ltd. | 7.67% |
| Torrent Pharmaceuticals Ltd. | 6.71% |
| Lupin Ltd. | 4.83% |
| Aurobindo Pharma Ltd. | 4.59% |
| Glenmark Pharmaceuticals Ltd. | 3.42% |
| Zydus Lifesciences Ltd. | 3.05% |
| Alkem Laboratories Ltd. | 3.04% |
| Mankind Pharma Ltd. | 2.79% |
Sectors
| Pharmaceuticals & Biotechnology | 99.9% |
Calculated by Growth Analyser from AMFI NAVs and the fund house's disclosed portfolio. Up to 1 year: total return; longer: CAGR. Research and education only; not investment advice. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not indicate future returns.